

FOI Request Response information

FOI request reference:	2015/152
Date request received:	24/07/2015
Date request responded to:	04/08/2015
Category:	Pharmacy
Tags:	Prescribing, biologics, biosimilar

Request Detail:

Info re Biologics and Biosimilar prescribing

I have a Freedom of Information request regarding biologics and biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last six months with the following drugs for the conditions listed below.

	Rheumatoid arthritis	Ankylosing spondylitis	Psoriatic arthritis
Abatacept (Orencia)			
Adalimumab (Humira)			
Apremilast (Otezla)			
Certolizumab Pegol (Cimzia)			
Etanercept (Enbrel)			
Golimumab (Simponi)			
Infliximab (Remicade)			
Infliximab biosimilar (Inflectra)			
Infliximab biosimilar (Remsima)			
Rituximab (MabThera)			
Secukinumab (Cosentyx)			
Tocilizumab (RoActemra)			
Ustekinumab (Stelara)			

Response Detail:

The Trust response to your recent information request is as follows:

	Rheumatoid arthritis	Ankylosing spondylitis	Psoriatic arthritis
Abatacept (Orencia)	6		
Adalimumab (Humira)	66	35	33
Apremilast (Otezla)			
Certolizumab Pegol (Cimzia)	20	2	5

Etanercept (Enbrel)	132	39	34
Golimumab (Simponi)	2		
Infliximab (Remicade)	8	1	1
Infliximab biosimilar (Inflectra)			
Infliximab biosimilar (Remsima)			
Rituximab (MabThera)	Approx 84		
Secukinumab (Cosentyx)			
Tocilizumab (RoActemra)	8		
Ustekinumab (Stelara)			

Please note where there are blanks this indicates no patients.